Induction of alkylator (Melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function

Molecular Pharmacology

Volumn 56, Issue 1, 1999, Pages 147-153

  Pu, Q Q ^a   Bezwoda, W R ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CAMPTOTHECIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; MELPHALAN;

ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DNA REPAIR; DRUG RESISTANCE; HUMAN; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULTRAVIOLET RADIATION;

EID: 0033035022     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.1.147     Document Type: Article

References (40)

1. Bailey HH, Gipp JJ, Ripple M, Wilding G and Mulcahy RT (1992) Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant Du-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res 52:5115-5118.
2. Batist G, Terres-Garcia S, Demuys JM, Greene D, Lehnert S, Rochon M and Panisci L (1989) Enhanced DNA cross-link removal: The apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line. Mol Pharmacol 36:224-230.
3. Bezwoda WR and Pu QQ (1997) In-vitro assessment of melphalan induced interstrand-DNA cross-links in lymphocytes provides a rapid method for assessment of alkylator sensitivity in patients with lymphoproliferative disorders. Int J Oncol 10:1061-1068.
4. Bradford MN (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Bungo M, Fujiwara Y, Kasahara K, Nakagawa K, Ohe Y, Irino S and Saijo N (1990) Decreased accumulation as a mechanism of resistance to cis-diamminedichloro-platinum (II) in human non-small cell lung cancer cell lines: Relation to DNA damage and repair. Cancer Res 50:2549-2553.
6. Chow KC, Johnson TL and Pearson GD (1985) A novel method for the detection and quantitation of eukaryotic topoisomerase I. Biotechniques 3:290-296.
7. De Jong S, Timmer-Bosscha H, DeVries E and Mulder NH (1993) Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand crosslink formation in a cisplatin resistant small cell lung carcinoma cell line. Int J Cancer 53:110-117.
8. De Jong S, Zijlstra JG, Mulder NH and DeVries EGE (1991a) Lack of cross resistance to fostreicin in a human small cell carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemather Pharmacol 28:461-464.
9. De Jong S, Zijlstra JG, Timmer-Bosscha H, Mulder NH and De Vries EGE (1991b) Detection of DNA cross-link in tumor cells with the ethidium bromide fluorescence assay. Int J Cancer 37:557-561.
10. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST and Mirabelli CK (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 20:8154-8160.
11. Drake FH, Zimmerman JP, Mccabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Matteern MR, Johnson RK, Crooke ST and Mirabelli CK (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells: Evidence for two forms of the enzyme. J Biol Chem 34:16739-16747.
12. Earnshaw WC, Halligan BC, Crooke CA, Heck MMS and Liu LF (1985) Topoisomerase II is a structural component of the mitotic chromosome scaffold. J Cell Biol 100:1706-1715.
13. Eder JP Jr, Chan VT, Ng SW, Rizvi NA, Zacharoulis S, Teicher BA and Schnipper LE (1995) DNA Topoisomerase IIα Expression is associated with alkylating agent resistance. Cancer Res 55:6109-6116.
14. Erickson LC, Bradley MO and Kohn KW (1997) Strand breaks in DNA from normal and transformed human cells treated with 1, 3- bis (2-chloroethyl)-1-nitrosourea. Cancer Res 37:3744-3750.
15. Ewig RAG and Kohn KW (1997) DNA damage and repair in mouse leukemia L1210 cell treated with nitrogen mustard, 1, 3 bis (2-chloroethyl)-1-nitrosourea, and other nitrosoureas. Cancer Res 37:2114-2122.
16. Frei E, Cucchi C and Rosowsky A (1985) Alkylating agent resistance: In vitro studies of human cell lines. Proc Natl Acad Sei USA 82:2158-2162.
17. Glisson BS and Ross WE (1987) DNA topoisomerase II: A primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther 32:89-106.
18. Gross-Bellard M, Oudet P and Chambon P (1972) Isolation of high-molecular-weight DNA from mammalian cells. Eur J Biochem 36:32-35.
19. Hansson J, Lewensohn R, Ringborg U and Nilsson B (1987) Formation and removal of DNA crosslinks induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 47:2631-2637.
20. Harker WG, Slade DL, Drake FH and Parr RL (1991) Mitoxantrone resistance in HL60 leukemia cells: Reduced nuclear topoisomerase II catalytic activity and drug induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30:9953-9961.
21. Heck MMS and Earnshaw WC (1986) Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 103:2569-2581.
22. Heck MMS, Hittelman WN and Earnshaw WC (1987) Differential expression of DNA topoisomerases during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85:1086-1090.
23. Hsiang Y, Wu H-Y and Liu LF (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 48:3230-3235.
24. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 58:351-375.
25. Liu LF and Miller KG (1981) Eukaryotic DNA topoisomerase: Two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 78:3487-3491.
26. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA and Ozols RF (1985) Radiation survival parameters of antineoplastic drug sensitive and resistant human ovarian cancer cell lines and their modification by glutathione sulfoximine. Cancer Res 45:2110-2115.
27. Marini JC, Miller KG and England PT (1980) Decatenation of kinetoplast DNA by topoisomerases. J Biol Chem 255:4976-4979.
28. Matsumoto Y, Fujiwara T, Honjo Y, Sasaoka N, Tsuchida T and Nagao S (1993) Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: Characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-II. J Surg Oncol 53:97-103.
29. Nelson WG, Pienta KJ, Barrack ER and Coffey DS (1986) The role of the nuclear matrix in the organization and function of DNA. Ann Rev Biophys Chem 15:457-475.
30. Olive PL, Wlodek D and Banath JP (1991) DNA double-strand breaks measured in individual cells subjected to gel electrophoresis. Cancer Res. 51:4671-4676.
31. Redwood WR and Colvin M (1980) Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res 40:1144-1149.
32. Richon VW, Schulte N and Eastman A (1990) Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in human non-small cell lung cancer cell lines: Relation to DNA damage and repair. Cancer Res 50:2549-2553.
33. Robson CN, Alexander J, Harris AL and Hickson ID (1985) Isolation and characterization of a Chinese hamster ovary cell line resistant to bifunctional nitrogen mustards. Cancer Res 45:5304-5309.
34. Ross WE, Ewing RAG and Kohn KW (1978) Differences between melphalan and nitrogen mustard in the formation and removal of DNA crosslinks Cancer Res 38:1502-1506.
35. Salacinski PRP, McLean C, Sykes JEC, Clement-Jones VV and Lowry PJ (1981) Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril (Iodogen). Anal Biochem 117: 136-146.
36. Tan KB, Mattern MR, Boyce RA and Schein PS (1987) Elevated DNA topoisomerase II activity in a nitrogen mustard resistant human cells. Prot Natl Acad Sci USA 84:7668-7671.
37. Twentyman PR and Luscombe MA (1987) Study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56:279-285.
38. Wang JC (1987) Recent studies of DNA topoisomerase. Biochim Biophys Acta 909: 1-9.
39. Woessner RD, Chung TDY, Hofmann GA, Mattem MR, Mirabelli CK, Drake FH and Johnson PK (1990) Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res 50:2901-2908.
40. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK and Drake FH (1991) Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerases II in NIH-3T3 cells. Cell Growth & Differ 2:209-214.